Dr. Giorgio Scagliotti on Taking a Targeted Approach to Immunotherapy in Lung Cancer

Giorgio V. Scagliotti, MD, PhD
Published: Tuesday, Aug 30, 2016


Giorgio V. Scagliotti, MD, PhD, Professor and Chair of Medical Oncology at the University of Turin and San Luigi Hospital, Orbassano, Italy, explains why immunotherapy treatments should be used with a targeted approach in lung cancer.
 
Immunotherapy is a sort of targeted therapy, says Scagliotti. Immunotherapy needs to be integrated into precision medicine, which by default requires the identification of a target. It is likely that there are multiple targets that can be identified for use with immunotherapy.
 
A diagnostic biomarker needs to be identified to isolate the type of patient that is getting a benefit from immunotherapy, says Scagliotti.
 

Giorgio V. Scagliotti, MD, PhD, Professor and Chair of Medical Oncology at the University of Turin and San Luigi Hospital, Orbassano, Italy, explains why immunotherapy treatments should be used with a targeted approach in lung cancer.
 
Immunotherapy is a sort of targeted therapy, says Scagliotti. Immunotherapy needs to be integrated into precision medicine, which by default requires the identification of a target. It is likely that there are multiple targets that can be identified for use with immunotherapy.
 
A diagnostic biomarker needs to be identified to isolate the type of patient that is getting a benefit from immunotherapy, says Scagliotti.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x